Sugammadex versus Neostigmine-Glycopyrrolate for Reducing the Risk of Postoperative Urinary Retention in High-Risk Patients Undergoing Otolaryngologic Surgery: A Randomised Controlled Trial
In brief
Sugammadex cut confirmed urinary retention from 19% to zero in a trial
Among 124 high-risk adults having elective ear, nose, and throat surgery, confirmed urinary retention requiring catheterisation occurred in 12 of 62 patients given neostigmine-glycopyrrolate and none of 62 given sugammadex. The trial suggests sugammadex can reduce this complication in this group, but it was small, and secondary outcomes were underpowered.
- Journal
- Anaesthesia, critical care & pain medicine (Q1)
- Published
- 10 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Yueh-Juh Lin, Kuang-Cheng Chan, Pei-Lin Lin
- PMID
- 43009017
- DOI
- 10.1016/j.accpm.2026.101989
Why clinicians should know about it
- Picked for Anesthesiology and Pain Medicine (top studies of the week, 15 November 2026): Compares anaesthetic reversal agents and postoperative complications
Abstract
BACKGROUND: Postoperative urinary retention (POUR) is a clinically important postoperative complication, particularly in patients at high risk for voiding dysfunction. Sugammadex reverses aminosteroid neuromuscular blockade without requiring concomitant antimuscarinic administration and may therefore reduce the risk of POUR compared with neostigmine-glycopyrrolate. METHODS: In this prospective randomised trial, 124 adults at high risk for POUR undergoing elective otolaryngologic surgery were randomly assigned (1:1) to receive neostigmine-glycopyrrolate or sugammadex for neuromuscular block reversal. The primary outcome was confirmed POUR, defined as inability to void requiring urinary catheterisation with an ultrasound-confirmed bladder volume ≥400 mL. Secondary outcomes included postoperative nausea and vomiting, haemodynamic events, patient-reported thirst intensity, and hospital length of stay. RESULTS: Confirmed POUR occurred in 12 of 62 patients (19.4%) in the neostigmine-glycopyrrolate group and in none of the 62 patients (0%) in the sugammadex group (risk difference, 19.4%; 95% CI, 9.5%-30.9%; P < 0.001; NNT = 6). Exploratory analysis showed that symptomatic urinary retention was also more frequent with neostigmine-glycopyrrolate than with sugammadex (40.3% vs. 4.8%; P < 0.001). No statistically significant between-group differences were observed in postoperative nausea and vomiting, haemodynamic events, thirst intensity, or hospital length of stay; secondary-outcome comparisons were not powered to detect between-group differences. CONCLUSIONS: Among patients at high risk for POUR undergoing elective otolaryngologic surgery, sugammadex reduced the risk of confirmed POUR compared with neostigmine-glycopyrrolate. Comparisons of secondary outcomes were underpowered and should be interpreted cautiously. REGISTRATION: ClinicalTrials.gov (NCT06398899; principal investigator: Pei-Lin Lin; registered on 5 March 2024).
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.